

Policy Name	Policy Number	Scope
Loncastuximab tesirine-lpyl (Zynlonta®)	MP-RX-FP-110-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Service Category

- | | |
|--|---|
| <input type="checkbox"/> Anesthesia | <input type="checkbox"/> Medicine Services and Procedures |
| <input type="checkbox"/> Surgery | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures | <input type="checkbox"/> DME/Prosthetics or Supplies |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Part B Drug |

Service Description

This document addresses the use of *Loncastuximab tesirine-lpyl (Zynlonta®)*, a CD19-directed antibody and alkylating agent conjugate approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

Background Information

Zynlonta is a monoclonal antibody-drug conjugate (ADC) that consists of an IgG1 antibody specific for CD19 and a small molecule component including an alkylating agent. The anticancer activity is due to the binding of the ADC to CD19-expressing cells and cleavage of alkylating component which induces cell death. The target CD19 is a surface protein found on B-cells and Zynlonta is indicated to treat diffuse large B-cell lymphoma (DLBCL). Post-Transplant Lymphoproliferative Disorders is treated the same way as relapsed/refractory DLBCL per National Comprehensive Cancer Network (NCCN).

The FDA approved indication for Zynlonta includes adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The indication includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. Zynlonta is approved under accelerated approval based on overall response rate; continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Definitions and Measures

- ECOG or Eastern Cooperative Oncology Group Performance Status: A scale and criteria used by doctors and researchers to assess how an individual's disease is progressing, assess how the disease affects the daily living abilities of the individual, and determine appropriate treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:
 - 0 = Fully active, able to carry on all pre-disease performance without restriction
 - 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work
 - 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
 - 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Loncastuximab tesirine-lpyl (Zynlonta®)	MP-RX-FP-110-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

- 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
- 5 = Dead
- Line of Therapy:
 - First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
 - Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
 - Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.
- Monoclonal antibody: A protein developed in the laboratory that can locate and bind to specific substances in the body and on the surface of cancer cells.
- Non-Hodgkin Lymphoma (NHL): A group of malignant solid tumors or lymphoid tissues. Refractory Disease: Illness or disease that does not respond to treatment.
- Relapse or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.

Approved Indications

- A. Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This approval for this specific use has been granted under accelerated approval, primarily relying on overall response rate and duration of response as key indicators. The ongoing approval status for this use case may depend on further confirmation and a comprehensive explanation of the clinical benefits observed in the subsequent confirmatory trials.

Other Uses

- i. None.

Medical Policy

Healthcare Services Department

Policy Name Loncastuximab tesirine-lpyl (Zynlonta®)	Policy Number MP-RX-FP-110-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
---	---	--

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS	Description
J9359	Injection, loncastuximab tesirine-lpyl, 0.075 mg [Zynlonta]

ICD-10	Description
C83.30	Diffuse large B-cell lymphoma, unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)

Policy Name	Policy Number	Scope
Loncastuximab tesirine-lpyl (Zynlonta®)	MP-RX-FP-110-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Loncastuximab tesirine-lpyl (Torisel®)

A. Criteria For Initial Approval *(Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.)*

- i. Individual has a diagnosis of progressive, relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, HIV-related diffuse large B-cell lymphomas (NCCN 2A), and high-grade B-cell lymphomas, and Post- Transplant Lymphoproliferative Disorders; **AND**
- ii. Individual is using Zynlonta as a single agent; **AND**
- iii. Individual has received at least two prior lines of systemic therapy; **AND**
- iv. Individual has a current ECOG performance status of 0-2 (NCT03589469).

B. Criteria For Continuation of Therapy

- i. MMM considers continuation of Loncastuximab tesirine-lpyl (Zynlonta®) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. The following information should be submitted for reauthorization:
 - A. A current oncology note documenting the patient's response to treatment showing no progression of disease.
 - B. Current imaging studies and other objective measures, as appropriate, showing no progression of disease when compared with previous results.

C. Authorization Duration

- i. Initial Approval Duration: Up to 6 months
- ii. Reauthorization Approval Duration: Up to 6 months

D. Conditions Not Covered

Medical Policy

Healthcare Services Department

Policy Name Loncastuximab tesirine-lpyl (Zynlonta®)	Policy Number MP-RX-FP-110-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
---	---	--

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. All other indications not included above;

OR

- ii. Individuals with active central nervous system (CNS) lymphoma.

Limits or Restrictions

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Recommended Dosing Schedule
Loncastuximab tesirine-lpyl (Zynlonta®) 10 mg SDV	Zynlonta is administered I.V. on Day 1 of each cycle (every 3 weeks), as follows: <ul style="list-style-type: none"> 0.15 mg/kg every 3 weeks for 2 cycles. 0.075 mg/kg every 3 weeks for subsequent cycles.
Exceptions	
None	

Reference Information

- Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
- DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
- DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
- NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 21, 2023.

Medical Policy

Healthcare Services Department

Policy Name Loncastuximab tesirine-lpyl (Zynlonta®)	Policy Number MP-RX-FP-110-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
---	---	--

- a. B-cell Lymphomas. V4.2023. Revised June 2, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Policy History

Revision Type	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review 11/17/2024	Wording and formatting changes. Coding Reviewed: Added ICD-10-CM D47.Z1 for PTLD to align with NCCN 2A criteria	3/14/2025	4/2/2025
Select Review 2/15/2024	Update statement for criteria for initial approval: Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met all approval criteria.	3/25/2024	5/9/2024
Policy Inception 11/17/2023	Elevance Health's Medical Policy adoption.	N/A	11/30/2023